Gunn rats bear a mutation within the uridine diphosphate glucuronosyltransferase-1a1 (Ugt1a1) gene resulting in high serum bilirubin levels as seen in Crigler-Najjar syndrome. In this study, the Gunn rat was used as an animal model for heritable liver dysfunction. Induced mesenchymal stem cells (iMSCs) derived from embryonic stem cells (H1) and induced pluripotent stem cells were transplanted into Gunn rats after partial hepatectomy. The iMSCs engrafted and survived in the liver for up to 2 months. The transplanted iMSCs differentiated into functional hepatocytes as evidenced by partially suppressed hyperbilirubinemia and expression of multiple human-specific hepatocyte markers such as albumin, hepatocyte nuclear factor 4α, UGT1A1, cytokeratin 18, bile salt export pump, multidrug resistance protein 2, Na/taurocholate-cotransporting polypeptide, and α-fetoprotein. These findings imply that transplanted human iMSCs can contribute to liver regeneration in vivo and thus represent a promising tool for the treatment of inherited liver diseases.
Get full access to this article
View all access options for this article.
References
1.
CriglerJFJr. and NajjarVA. (1952). Congenital familial nonhemolytic jaundice with kernicterus. Pediatrics, 10:169–180.
2.
Ruud HansenTW. (2010). Phototherapy for neonatal jaundice—therapeutic effects on more than one level?. Semin Perinatol, 34:231–234.
3.
RamyN, GhanyEA, AlsharanyW, NadaA, DarwishRK, RabieWA and AlyH. (2016). Jaundice, phototherapy and DNA damage in full-term neonates. J Perinatol, 36:132–136.
4.
van DijkR, BeuersU and BosmaPJ. (2015). Gene replacement therapy for genetic hepatocellular jaundice. Clin Rev Allergy Immunol, 48:243–253.
5.
JornsC, NowakG, NemethA, ZemackH, MörkLM, JohanssonH, GramignoliR, WatanabeM, KaradagiA, et al. (2016). De novo donor-specific HLA antibody formation in two patients with Crigler–Najjar Syndrome Type I following human hepatocyte transplantation with partial hepatectomy preconditioning. Am J Transplant, 16:1021–1030.
6.
GunnCK. (1944). Hereditary acholuric jaundice in the rat. Can Med Assoc J, 50:230–237.
7.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopDj and HorwitzE. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
8.
CrisanM, YapS, CasteillaL, ChenCW, CorselliM, ParkTS, AndrioloG, SunB, ZhengB, et al. (2008). A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell, 3:301–313.
9.
SatoY, ArakiH, KatoJ, NakamuraK, KawanoY, KobuneM, SatoT, MiyanishiK, TakayamaT, et al. (2005). Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood, 106:756–763.
10.
KuoTK, HungSP, ChuangCH, ChenCT, ShihYR, FangSC, YangVW and LeeOK. (2008). Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology, 134:2111–2121, 2121.e1.
11.
van PollD, ParekkadanB, ChoCH, BerthiaumeF, NahmiasY, TillesAW and YarmushML. (2008). Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology, 47:1634–1643.
12.
KramannR, SchneiderRK, DiRoccoDP, MachadoF, FleigS, BondziePA, HendersonJM, EbertBL and HumphreysBD. (2015). Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell, 16:51–66.
13.
WalkerN, BadriL, WettlauferS, FlintA, SajjanU, KrebsbachPH, KeshamouniVG, Peters-GoldenM and LamaVN. (2011). Resident tissue-specific mesenchymal progenitor cells contribute to fibrogenesis in human lung allografts. Am J Pathol, 178:2461–2469.
FrobelJ, HemedaH, LenzM, AbagnaleG, JoussenS, DeneckeB, SarićT, ZenkeM and WagnerW. (2014). Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells. Stem Cell Rep, 3:414–422.
16.
WangX, KimbrelEA, IjichiK, PaulD, LazorchakAS, ChuJ, KourisNA, YavanianGJ, LuSJ, et al. (2014). Human ESC-derived MSCs outperform bone marrow MSCs in the treatment of an EAE model of multiple sclerosis. Stem Cell Rep, 3:115–130.
17.
HawkinsKE, CorcelliM, DowdingK, RanzoniAM, VlahovaF, HauKL, HunjanA, PeeblesD, GressensP, et al. (2018). Embryonic stem cell-derived mesenchymal stem cells (MSCs) have a superior neuroprotective capacity over fetal MSCs in the hypoxic-ischemic mouse brain. Stem Cells Transl Med, 7:439–449.
18.
LianQ, ZhangY, ZhangJ, ZhangHK, WuX, ZhangY, LamFF, KangS, XiaJC, et al. (2010). Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation, 121:1113–1123.
19.
GruenlohW, KambalA, SondergaardC, McGeeJ, NaceyC, KalomoirisS, PepperK, OlsonS, FierroF and NoltaJA. (2011). Characterization and in vivo testing of mesenchymal stem cells derived from human embryonic stem cells. Tissue Eng Part A, 17:1517–1525.
20.
KimbrelEA, KourisNA, YavanianGJ, ChuJ, QinY, ChanA, SinghRP, McCurdyD, GordonL, LevinsonRD and LanzaR. (2014). Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties. Stem Cells Dev, 23:1611–1624.
21.
MuracaM, FerraressoC, VileiMT, GranatoA, QuartaM, CozziE, RuggeM, PauwelynKA, CarusoM, et al. (2007). Liver repopulation with bone marrow derived cells improves the metabolic disorder in the Gunn rat. Gut, 56:1725–1735.
22.
ChenY, LiY, WangX, ZhangW, SauerV, ChangCJ, HanB, TchaikovskayaT, AvsarY, et al. (2015). Amelioration of hyperbilirubinemia in Gunn rats after transplantation of human induced pluripotent stem cell-derived hepatocytes. Stem Cell Rep, 5:22–30.
23.
Mirmalek-SaniSH, TareRS, MorganSM, RoachHI, WilsonDI, HanleyNA and OreffoRO. (2006). Characterization and multipotentiality of human fetal femur-derived cells: implications for skeletal tissue regeneration. Stem Cells, 24:1042–1053.
24.
MeggesM, OreffoRO and AdjayeJ. (2016). Episomal plasmid-based generation of induced pluripotent stem cells from fetal femur-derived human mesenchymal stromal cells. Stem Cell Res, 16:128–132.
25.
ChenYS, PelekanosRA, EllisRL, HorneR, WolvetangEJ and FiskNM. (2012). Small molecule mesengenic induction of human induced pluripotent stem cells to generate mesenchymal stem/stromal cells. Stem Cells Transl Med, 1:83–95.
26.
DirksWG and DrexlerHG. (2013). STR DNA typing of human cell lines: detection of intra- and interspecies cross-contamination. Methods Mol Biol, 946:27–38.
27.
HigginsGM and AndersonRM. (1931). Experimental pathology of the liver. I. Restoration of the liver of the white rat following partial surgical removal. Arch Pathol Lab Med, 12:186–202.
28.
HerebianD and MayatepekE. (2012). Analysis of bile acids by tandem mass spectrometry. In: Hepatobiliary Transport in Health and Disease. HäussingerD, KeitelV, KubitzR, eds. Walter De Gruyter GmbH Co. KG, Berlin/Boston, pp 277–287.
29.
KordesC, SawitzaI, GötzeS, HerebianD and HäussingerD. (2014). Hepatic stellate cells contribute to progenitor cells and liver regeneration. J Clin Invest, 124:5503–5515.
30.
O'Hagan-WongK, NadeauS, Carrier-LeclercA, ApablazaF, HamdyR, Shum-TimD, RodierF and ColmegnaI. (2016). Increased IL-6 secretion by aged human mesenchymal stromal cells disrupts hematopoietic stem and progenitor cells' homeostasis. Oncotarget, 7:13285–13296.
31.
VassilopoulosG, WangPR and RussellDW. (2003). Transplanted bone marrow regenerates liver by cell fusion. Nature, 422:901–904.
32.
WangX, WillenbringH, AkkariY, TorimaruY, FosterM, Al-DhalimyM, LagasseE, FinegoldM, OlsonS and GrompeM. (2003). Cell fusion is the principal source of bone marrow-derived hepatocytes. Nature, 422:897–901.
33.
VassilopoulosG and RussellDW. (2003). Cell fusion: an alternative to stem cell plasticity and its therapeutic implications. Curr Opin Genet Dev, 13:480–485.
34.
SullivanS and EgganK. (2006). The potential of cell fusion for human therapy. Stem Cell Rev, 2:341–349.
35.
García-CañaverasJC, DonatoMT, CastellJV and LahozA. (2012). Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method. J Lipid Res, 53:2231–2241.
36.
AggarwalS and PittengerMF. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105:1815–1822.
37.
KaplanJM, YoudME and LodieTA. (2011). Immunomodulatory activity of mesenchymal stem cells. Curr Stem Cell Res Ther, 6:297–316.
38.
TrounsonA and McDonaldC. (2015). Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell, 17:11–22.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
